Health
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides immitis NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapi
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i_32n6NFUT7JH9rPdqYNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/i_32n6NFUT7JH9rPdqYNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides immitis","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":300,"olType":false},{"type":"text","content":"NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new clinical and translational data presented at the American Thoracic Society (ATS) International Conference 2026 and the simultaneous publication in Clinical Immunology Communications1 describing the use of sequential immunotherapy with MiNK’s off-the-shelf iNKT cell therapy, agenT-797 and N-803, an IL-15 superagonist, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia.","length":814,"tagName":"p"},{"type":"text","content":"The poster, titled 'Novel Invariant Natural Killer T Cell (agenT-797) and Interleukin-15 Superagonist (N-803) Combination Immunotherapy for Unresolving Coccidioides immitis Infection with Concurrent ARDS,' was presented by Teres...